Current Treatment Options for Equine Laminitis: Evidence, Limitations and Gaps

Managing a horse with acute or chronic laminitis remains one of equine medicine's most challenging clinical tasks. A range of interventions are used in practice, but the evidence base underpinning them is variable — and no approved pharmacological treatment has been shown in controlled trials to directly limit lamellar tissue injury. This article provides a structured review for veterinary professionals, assessing the evidence quality behind each intervention and identifying where the gaps lie.

Internal links: For the pathophysiology that informs treatment rationale, see What Is Equine Laminitis? A Scientific Overview of Lamellar Pathophysiology. For the specific challenges of chronic disease, see Chronic and Refractory Laminitis: Why the Unmet Need Drives Research. For how the PTP-102 investigational programme fits into this context, see The Oligofructose-Induced Laminitis Model: What It Measures and What It Does Not.

Framework: What "Evidence" Means Here

Evidence quality in equine laminitis treatment is generally low by the standards of human medicine. Most interventions are supported by:

• Expert consensus and clinical experience

• Case series or retrospective studies

• Experimental animal model studies (not equivalent to clinical trials)

• Extrapolation from human or other animal medicine

Very few have been subjected to randomised controlled trials in clinical equine populations. Readers should interpret "evidence supports" cautiously: it typically means "the evidence available is consistent with benefit" rather than "efficacy has been definitively proven."

Analgesic and Anti-Inflammatory Agents

NSAIDs

Non-steroidal anti-inflammatory drugs — particularly phenylbutazone and flunixin meglumine — are the most widely used pharmacological agents in acute laminitis management.

Rationale: Inhibition of cyclooxygenase (COX) enzymes reduces prostaglandin synthesis, providing analgesia and modulating the inflammatory response.

Evidence: Controlled trial data in laminitis are limited. NSAIDs demonstrably reduce pain markers and improve horse comfort in clinical and experimental settings. Whether they limit lamellar tissue damage — rather than masking pain while damage continues — is less clear. There is theoretical concern that effective analgesia may increase weight-bearing before structural stability is re-established, though this has not been formally demonstrated.

Limitations and risks:

• Gastrointestinal toxicity (right dorsal colitis, gastric ulceration) with prolonged or high-dose use

• Renal effects, particularly with concurrent dehydration or NSAID combinations

• No demonstrated disease-modifying effect on lamellar tissue

Selective COX-2 inhibitors (e.g., meloxicam, firocoxib) offer a potentially improved gastrointestinal safety profile and are increasingly used, but comparative efficacy data specific to laminitis are limited.

Opioids and Other Analgesics

Opioid analgesics are used in acute severe laminitis, typically under hospitalised conditions. Butorphanol is most commonly used in the equine context. Evidence for effect on laminitis-specific outcomes is largely from case experience; controlled data are absent.

Mechanical Support

Deep Bedding and Stall Rest

Providing deep, conforming bedding (sand, shavings, or rubber matting) to support the solar surface and reduce pressure on the toe region is universal practice. The biomechanical rationale is sound and consistent with the anatomy of lamellar loading. Formal evidence for specific bedding types is limited.

Orthopaedic Shoeing and Trimming

A range of farriery approaches aim to reduce DDFT tension, redistribute load away from the toe, and provide solar support:

• Deep digital flexor tendon offloading: Heart-bar shoes, frog-support pads, or foam pads placed under the frog and palmar foot reduce the rotational moment exerted by the DDFT on the distal phalanx. Evidence is largely biomechanical and case series based.

• Breakover modification: Moving the shoe's breakover point palmarly reduces the force peak on the lamellar interface during the push-off phase of gait.

• Radiograph-guided trimming: Using lateromedial radiographs to establish parallel alignment of the solar surface with the distal phalanx (the "ground parallel P3" concept) aims to optimise load distribution.

Farriery approaches are widely considered among the most important management tools in laminitis, but evidence from controlled trials is absent.

Cryotherapy

Continuous digital cryotherapy — applied from the time of triggering event recognition through the developmental and early acute phase — has the strongest experimental evidence of any current laminitis intervention, particularly for carbohydrate-overload and sepsis-associated cases.

Rationale: Cooling reduces tissue metabolic demand and may reduce vascular permeability and inflammatory mediator activity in lamellar tissue during the period of ischaemic and inflammatory stress.

Evidence: Experimental carbohydrate-overload studies in horses have demonstrated that continuous cryotherapy (targeting digital temperature <10°C) during the developmental phase significantly reduces histological lamellar damage compared to controls. This represents the closest to controlled experimental evidence available for any laminitis intervention.

Limitations:

• Requires practical capacity to apply continuous cooling over 24–72 hours

• Evidence is strongest for experimental model conditions; whether protection is equivalent in naturally occurring disease has not been established in formal clinical trials

• Not effective after structural damage is established; a preventive, not a rescue, intervention

Endocrine and Metabolic Management

For endocrinopathic laminitis — associated with EMS or PPID — managing the underlying endocrine dysfunction is essential to reducing recurrence and slowing progression.

• Insulin management: Dietary restriction of non-structural carbohydrates (NSC), weight loss in overweight animals, and exercise (where tolerable) are cornerstones of EMS management. No pharmacological agent is specifically approved for equine insulin dysregulation, though metformin is used off-label with limited evidence.

• PPID treatment (pergolide): Dopamine agonist therapy reduces ACTH dysregulation and is associated with clinical improvement in many horses. Evidence quality is moderate; controlled trial data exist but are limited in scope.

These interventions address the trigger rather than the lamellar tissue directly. They are important for long-term management but do not constitute disease-modifying treatment of lamellar injury.

Vasoactive Agents

Several vasoactive agents have been investigated in experimental laminitis models, based on the vascular dysfunction hypothesis.

• Acepromazine: Has been used to promote digital vasodilation; experimental data are inconsistent and clinical trial evidence absent.

• Isoxsuprine: Historically used; little credible modern evidence for efficacy.

• Pentoxifylline: Rheological effects on blood viscosity proposed as beneficial; evidence limited.

None of these agents has demonstrated efficacy in controlled clinical trials. Their use is largely historical or anecdotal.

Summary of Evidence Tiers

The Gap That Remains

The table above illustrates the central problem: no currently approved intervention directly limits lamellar tissue injury or promotes lamellar repair in a way demonstrated in controlled clinical trials. The strongest existing evidence (cryotherapy) applies only to a narrow preventive window in experimental conditions. For horses with established acute or chronic disease, management is largely symptom control and compensatory support.

This is the gap that motivates continued research into novel pharmacological approaches. Programmes such as PTP-102 — at present at the investigational stage — aim to address whether specific molecular targets within the lamellar inflammatory or vascular cascade can be engaged therapeutically. Readers interested in how PTP-102 studies were designed and what their findings support are directed to the PTP-102 Research section of this portal.

This article is intended for equine veterinary professionals. Evidence quality assessments reflect the author's reading of published veterinary literature and do not represent formal systematic review conclusions. PTP-102 is an investigational product and has not been approved by any regulatory authority.

Content notice: This article was prepared with AI assistance by the Byrock Editorial Team and has not been independently verified by an external consultant, regulatory authority, or peer reviewer. It does not represent the position of any regulatory body. Readers are encouraged to consult primary sources and qualified specialists.